Pharmacokinetics of Belumosudil and Its Metabolites in Individuals With Hepatic Impairment

Documenti analoghi

• In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor
  di: Olivier Schueller, et al.
  Pubblicazione: (2025)
• The Effect of Ecopipam on the Pharmacokinetics of Concomitant Medications
  di: Virginia D. Schmith, et al.
  Pubblicazione: (2026)
• Pharmacokinetics of Bocidelpar, ASP0367, in Renal and Hepatic Impairment: Results From Two Phase 1 Studies
  di: Megumi Iwai, et al.
  Pubblicazione: (2025)
• Two‐Part Phase 1 Study to Evaluate the Taste Profile of Novel Belumosudil Oral Suspensions and Assess the Relative Bioavailability and Food Effect of the Selected Belumosudil Oral Suspension Compared With Oral Tablet Reference in Healthy Male Participants
  di: Olivier Schueller, et al.
  Pubblicazione: (2024)
• Pharmacokinetics and Toxicity of Dimethylacetamide and Its Metabolite in Pediatric Patients Treated With High Dose Intravenous Busulphan
  di: Fadwa Benkessou, et al.
  Pubblicazione: (2025)